#For clinicians
Written for prescribing clinicians, with full citation chains.
Can incretins ease psoriasis inflammation?
A 2026 editorial asks whether tirzepatide-class incretin therapy quiets inflammation biologics leave behind in psoriasis. A hypothesis, not a trial result.
COMBINE 4: IcoSema vs insulin glargine
COMBINE 4 put once-weekly IcoSema against daily insulin glargine U100 in type 2 diabetes. HbA1c fell further, and bodyweight moved the other way.
Tirzepatide, blood pressure, cholesterol
A SURMOUNT post hoc analysis scores tirzepatide on all three targets at once. Between 32% and 38% of participants hit every one. Composites read differently.
What semaglutide does to daily life in MASH
A new ESSENCE analysis puts a number on how people with MASH feel on semaglutide: a small EQ-5D utility gain, and why payers will care about it.
Does the eGFR dip explain heart benefit?
A 376-patient Saudi cohort asked whether the early eGFR change explains heart outcomes on dapagliflozin plus semaglutide. The answer was no.
Japan tirzepatide dispensing and dose mix
Japan's claims data show 86.2% of tirzepatide kits dispensed outside medical institutions, with higher strengths nearly doubling their share in ten months.
Peptides for tendon recovery: the evidence
BPC-157 and TB-500 have promising animal data for tendon and ligament repair, but almost no human trial evidence. Here is how to weight it.
Tendon recovery peptides: evidence grade
BPC-157 has consistent animal tendon data. TB-500 has one human ophthalmic RCT. Neither has an RCT for tendons or ligaments. An honest evidence grade.
GH-axis peptides: weighing the evidence
Tesamorelin, CJC-1295 and ipamorelin sit on three different rungs of the evidence ladder. Here is how to weight what each one actually shows.
GH-axis peptides: grading the evidence
Tesamorelin has two Phase 3 RCTs and FDA approval. CJC-1295 has two early-phase studies. Ipamorelin has one PK study and a negative Phase 2.
Peptides for injury recovery: the evidence
BPC-157 and TB-500 are the most-asked injury-recovery peptides. Here is what is trial-supported, what is animal-only, and what is just anecdote.
Peptide longevity: what the evidence shows
What trial data supports for peptides marketed for longevity: from GLP-1 cardiovascular outcomes to preclinical Epitalon and GHK-Cu research.